Last reviewed · How we verify
rAvPAL-PEG
At a glance
| Generic name | rAvPAL-PEG |
|---|---|
| Also known as | Recombinant Anabaena variabilis phenylalanine ammonia lyase, Pegvaliase |
| Sponsor | BioMarin Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
- A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
- A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
- Immune Modulation During Palynziq® Treatment in Adults (IMPALA) (PHASE4)
- Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
- Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
- Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria (PHASE3)
- Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rAvPAL-PEG CI brief — competitive landscape report
- rAvPAL-PEG updates RSS · CI watch RSS
- BioMarin Pharmaceutical portfolio CI